stockrow
Friday 6 November 2026
Export XCUR’s income statement to Excel — free account
Exicure, Inc.
XCUR Healthcare Biotechnology
Exicure, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $500,000.00, down 98.3% from fiscal 2022.
- EPS
- +56.1%
- Free cash flow
- +65.4%
Quarter to June 2026, against a year earlier
0.91
0.02
+2.25%
Follow XCUR
Alert me
Exicure, Inc. (XCUR) P/E ratio
Exicure, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.1× (June 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.2× | 0.00% |
| FY2016 | 0.2× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
84
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| XCUR Exicure, Inc. | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)